Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors

被引:14
|
作者
Shakya, Anshul [1 ]
Chikhale, Rupesh V. [2 ]
Bhat, Hans Raj [1 ]
Alasmary, Fatmah Ali [3 ]
Almutairi, Tahani Mazyad [3 ]
Ghosh, Surajit Kumar [1 ]
Alhajri, Hassna Mohammed [3 ]
Alissa, Siham A. [4 ]
Nagar, Shuchi [5 ]
Islam, Md Ataul [6 ,7 ,8 ]
机构
[1] Dibrugarh Univ, Fac Sci & Engn, Dept Pharmaceut Sci, Dibrugarh 786004, Assam, India
[2] Univ East Anglia, Sch Pharm, Norwich Res Pk, Norwich NR5 7TJ, Norfolk, England
[3] King Saud Univ, Coll Sci, Chem Dept, POB 2455, Riyadh 11451, Saudi Arabia
[4] Princess Nourah Bint Abdulrahman Univ, Coll Sci, Dept Chem, Riyadh 11671, Saudi Arabia
[5] Dr DY Patil Vidyapeeth, Dr DY Patil Biotechnol & Bioinformat Inst, Bioinformat Res Ctr, Pune, Maharashtra, India
[6] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Div Pharm & Optometry, Manchester, Lancs, England
[7] Univ Kwazulu Natal, Sch Hlth Sci, Westville Campus, Durban, South Africa
[8] Univ Pretoria, Fac Hlth Sci, Dept Chem Pathol, Pretoria, South Africa
关键词
Morus alba Linn; SARS-CoV-2; TMPRSS2; Virtual screening; Molecular docking; MOLECULAR-DYNAMICS; ROOT BARK; VIRUS; CORONAVIRUS; ACCURACY; TARGET; ACE2;
D O I
10.1007/s11030-021-10209-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transmembrane protease serine-2 (TMPRSS2) is a cell-surface protein expressed by epithelial cells of specific tissues including those in the aerodigestive tract. It helps the entry of novel coronavirus (n-CoV) or Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the host cell. Successful inhibition of the TMPRSS2 can be one of the crucial strategies to stop the SARS-CoV-2 infection. In the present study, a set of bioactive molecules from Morus alba Linn. were screened against the TMPRSS2 through two widely used molecular docking engines such as Autodock vina and Glide. Molecules having a higher binding affinity toward the TMPRSS2 compared to Camostat and Ambroxol were considered for in-silico pharmacokinetic analyses. Based on acceptable pharmacokinetic parameters and drug-likeness, finally, five molecules were found to be important for the TMPRSS2 inhibition. A number of bonding interactions in terms of hydrogen bond and hydrophobic interactions were observed between the proposed molecules and ligand-interacting amino acids of the TMPRSS2. The dynamic behavior and stability of best-docked complex between TRMPRSS2 and proposed molecules were assessed through molecular dynamics (MD) simulation. Several parameters from MD simulation have suggested the stability between the protein and ligands. Binding free energy of each molecule calculated through MM-GBSA approach from the MD simulation trajectory suggested strong affection toward the TMPRSS2. Hence, proposed molecules might be crucial chemical components for the TMPRSS2 inhibition. [GRAPHICS] .
引用
收藏
页码:265 / 278
页数:14
相关论文
共 50 条
  • [11] Structure-based identification of potential SARS-CoV-2 main protease inhibitors
    Khan, Shama
    Fakhar, Zeynab
    Hussain, Afzal
    Ahmad, Aijaz
    Jairajpuri, Deeba Shamim
    Alajmi, Mohamed F.
    Hassan, Md. Imtaiyaz
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (08): : 3595 - 3608
  • [12] Transmembrane protease serine 2 (TMPRSS2) inhibitors screened from an Fv-antibody library for preventing SARS-CoV-2 infection
    Jung, Jaeyong
    Sung, Jeong Soo
    Kwon, Soonil
    Bae, Hyung Eun
    Kang, Min-Jung
    Jose, Joachim
    Lee, Misu
    Pyun, Jae-Chul
    RSC MEDICINAL CHEMISTRY, 2025,
  • [13] Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors
    Huang, Li
    Zhu, Lei
    Xie, Hua
    Goodwin, Jeffery Shawn
    Rana, Tanu
    Xie, Lan
    Chen, Chin-Ho
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
  • [14] Allosteric inhibitors of the main protease of SARS-CoV-2
    Samrat, Subodh Kumar
    Xu, Jimin
    Xie, Xuping
    Gianti, Eleonora
    Chen, Haiying
    Zou, Jing
    Pattis, Jason G.
    Elokely, Khaled
    Lee, Hyun
    Li, Zhong
    Klein, Michael L.
    Shi, Pei-Yong
    Zhou, Jia
    Li, Hongmin
    ANTIVIRAL RESEARCH, 2022, 205
  • [15] Peroxide derivatives as SARS-CoV-2 entry inhibitors
    Zhang, Ding-qi
    Ma, Qin-hai
    Yang, Meng-chu
    Belyakova, Yulia Yu.
    Yang, Zi-feng
    Radulov, Peter S.
    Chen, Rui-hong
    Yang, Li-jun
    Wei, Jing-yuan
    Peng, Yu-tong
    Zheng, Wu-yan
    Yaremenko, Ivan A.
    Terent, Alexander O.
    Coghi, Paolo
    Wong, Vincent Kam Wai
    VIRUS RESEARCH, 2024, 340
  • [16] Developing inhibitors of the SARS-CoV-2 main protease
    Seitz, Christian
    Markota, Vedran
    Sztain-Pedone, Terra
    Esler, Morgan
    Moghadasi, Arad
    Kennelly, Samantha
    Demir, Ozlem
    Aihara, Hideki
    Harki, Daniel A.
    Harris, Reuben
    McCammon, J. Andrew
    Amaro, Rommie E.
    BIOPHYSICAL JOURNAL, 2022, 121 (03) : 192A - 192A
  • [17] Potential SARS-CoV-2 main protease inhibitors
    Banerjee, Riddhidev
    Perera, Lalith
    Tillekeratne, L. M. Viranga
    DRUG DISCOVERY TODAY, 2021, 26 (03) : 804 - 816
  • [18] On the origins of SARS-CoV-2 main protease inhibitors
    Janin, Yves L.
    RSC MEDICINAL CHEMISTRY, 2024, 15 (01): : 81 - 118
  • [19] Peptidomimetic inhibitors of SARS-COV-2 main protease
    Angeles Bonache, Ma.
    Algar, Sergio
    Medina, Jessy
    Diaz-Agustin, Aitor
    Bueno, Paula
    Castro, Victoria
    Fabrega, Montserrat
    Coll, Miquel
    Garaigorta, Urtzi
    Gastaminza, Pablo
    Martin Martinez, Mercedes
    Gonzalez-Muniz, Rosario
    JOURNAL OF PEPTIDE SCIENCE, 2024, 30
  • [20] Perspectives on SARS-CoV-2 Main Protease Inhibitors
    Gao, Kaifu
    Wang, Rui
    Chen, Jiahui
    Tepe, Jetze J.
    Huang, Faqing
    Wei, Guo-Wei
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (23) : 16922 - 16955